University of Pennsylvania drives new discoveries in cancer immunotherapy research on an international scale, and pioneered the first FDA-approved CAR-T cell therapy. Penn’s award-winning doctors and scientists focus on training immune cells to recognize and hunt cancer cells. PICI at Penn extends this work and supports laboratory studies and clinical trials, recruitment of talented new faculty and opportunities for early-career investigators who will train at Penn. Carl June, MD | Director Saar Grill, MBBS, PhD, FRACP | Co-Director E. John Wherry, PhD | Co-Director All Investigators Related Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size Clinical Trial The PRINCE Trial Research Update A Bubble of Hope for Cancer: the Exosome in Immunotherapy Press Release Parker Institute researchers publish first major scientific paper in Nature Announcement, Patient Story Living Proof: Cancer Vaccine Recipients Bring Their Sto Research Update Cancer Vaccines: A New Era in Cancer Treatment Announcement, Press Release Dr. Sager Named Recipient of PICI’s Inaugural YIA Award Announcement, Press Release PICI Brings Power of Integrated Network to ASCO 2026 Announcement, Press Release PICI Welcomes Aimee Johnson as Chief Marketing Officer
Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size